Autotransfusion systems are medical device that collects and processes the patient's blood during a specific surgical procedure, thereby reducing the need for any blood transfusion from an external donor. According to Marketstack, the Global Autotransfusion Systems Market is expected to grow considerably during the forecasted period. Factors such as the rising number of cardiac and orthopaedic surgeries are expected to drive the Global Autotransfusion Systems Market in the forecasted period. Further, the scarcity of donated or allogeneic blood owing to the extensive use of autotransfusion systems, which are highly useful in purifying a patient's blood, is expected to drive the Global Autotransfusion Systems Market in the forecasted period. Furthermore, there is a rising demand for organ transplants for autologous blood transfusion for patients' blood management during the organ transplantation procedure, which is expected to drive the Global Autotransfusion Systems Market in the forecasted period. However, Concerns about the high cost of these systems, increased public awareness about the risks associated with this system, and various initiatives and programmes organized by governments to promote blood donation globally are the major factors acting as restraints are expected to restrain the Global Autotransfusion Systems Market in the forecasted period.

The cardiac surgeries segment is expected to occupy a vital market share due to the increasing prevalence of cardiac diseases and recommendations for autologous transfusion during cardiovascular surgeries. Autologous transfusion is an easy, valuable concept to save blood and minimize the transfusion requirement in the postoperative period in cardiopulmonary bypass and open-heart surgeries. It reduces the need for allogeneic blood products in adult cardiac surgery. Preoperative autologous is a safe and efficient option for allogeneic transfusion. Patients suffering from rare blood phenotypes or allogeneic antibodies are expected to benefit from autologous transfusion, as compatible allogeneic blood may not always be available. Allogeneic transfusion is associated with potential complications that can be removed or reduced while autologous blood is administered. These complications include alloimmunization, transfusion-transmitted infectious diseases, hemolytic reactions, and allergic and febrile reactions. The withdrawal of autologous blood earlier conducting cardiopulmonary bypass preserves red cell mass, protects the platelets, and decreases allogeneic transfusion needs. The appropriate condition for autologous blood donation is elective cardiac surgery, with a high probability of blood transfusion. Such an increased number of cardiovascular surgeries leads to the extensive usage of auto-transfusion systems, thereby contributing to the market's growth. Cell salvage and blood transfusions are critical components of blood conservation during every surgical operation. In addition, increased blood transfusion diagnostics are done to detect any infection in the blood before the transfusion. There is a greater focus on ignoring the hazards connected with allogeneic transfusions, along with an expanding number of bleeding-intensive surgeries. Furthermore, the segment's growth is also increasing due to the growing need for more donated or allogenic blood. Therefore, owing to the factors mentioned above, the feature is expected to occupy a significant share of the market and grow over the forecasted period.

North America is anticipated to dominate the overall market throughout the forecasted period. The market growth is owing to factors such as the presence of key players, many surgeries in the region, and established healthcare infrastructure. Blood transfusions and intra and postoperative cell salvage are crucial components of blood conservation throughout every surgical treatment. Growing cases of high-bleeding procedures and the emphasis on minimizing problems from allogeneic transfusions are also anticipated to drive the growth of the autotransfusion systems market over the forecast period. An autologous blood program awareness conducted in hospitals helps doctors and patients understand the benefits of autologous transfusion. Preoperative autologous transfusion involves collecting and storing a patient's blood for a while. Blood collection in advance is usually impossible because there is no set date for liver transplants, except for cases involving living donors. As a result, intraoperative blood salvage autotransfusion (IBSA) is used as an autologous transfusion strategy. IBSA involves recovering blood lost during the procedure and reintroducing it into the patient's body via infusion. This eliminates the need for an allogeneic blood transfusion, which could affect recipient survival and have an immunosuppressive effect.

Allogeneic transfusion raises the risk of viral infection transmission and transfusion errors among patients. This, in turn, is contributing to the demand for autotransfusion systems in organ transplant procedures to manage blood loss and increase safety and effectiveness during the process. As a stand-alone component of a Patient Blood Management program, it can efficiently develop clinical results. Patients can benefit from potentially substantial cost savings and, more importantly, better results since an immune response is improved, infection risk is lessened, the morbidity rate is down, and the time required for hospital stay can be shorter. There is no need for blood bank reserves. Autotransfusion systems are portable and straightforward to set up. Furthermore, it reduces illness and prevents the unfavourable effects of regular donor blood transfusions and pre-done blood. This surges efficiency and adds value while enabling hospitals to achieve exceptional results and increase revenue growth in this segment.

The market key players are Beijing Zhongke Zhengfang Technology Co., LTD, Braile Biomédica, Fresenius SE & Co. KGaA Gen World Medical Devices (India), and Haemonetics Corporation.

In September 2022, i-SEP received CE-marking and initiated marketing of its autotransfusion medical device, Same by i-SEP. It is one of the intraoperative autotransfusion technologies capable of preserving platelets and the patient's red blood cells.

In June 2022, Haemonetics launched a manufacturing centre of Excellence in Clinton, Pennsylvania, to develop auto-transfusion systems. The custom-built facility is expected to expand the product offerings of the company.

Global Autotransfusion Systems Market report provides deep insight into the Industrial market's current and future state across various regions. The study comprehensively analyses the Autotransfusion Systems Market by segmenting based on Type (Products, Accessories, Autotransfusion Types, Postoperative Autotransfusion Systems, Dual-Mode Autotransfusion Systems), Application (Cardiac Surgeries, Orthopedic Surgeries, Organ Transplantation, Trauma Procedures, Others), End-Use (Hospitals, ASCs, Others), and Geography (Asia-Pacific, North America, Europe, South America, and Middle East & Africa). The report examines the market drivers and restraints and the impact of COVID-19 on market growth in detail. The study covers emerging market trends, development, opportunities, and challenges in the industry. This report also covers extensively researched competitive landscape sections with prominent companies and profiles, including their market shares and projects.